Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARTEMIS-003: A Phase 2, Open-label, Multi-center Study to Evaluate Efficacy, Safety, and Pharmacokinetics, of Intravenous Administration of HS-20093 in Patients With Metastasis Castration Resistant Prostate Cancer and Advanced Solid Tumors Who Have Progressed Following at Least One Prior Therapy

NCT06001255 is registered in ClinicalTrials.gov with Hansoh BioMedical R&D Company as lead sponsor.

NCT NCT06001255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06001255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARTEMIS-003: A Phase 2, Open-label, Multi-center Study to Evaluate Efficacy, Safety, and Pharmacokinetics, of Intravenous Administration of HS-20093 in Patients With Metastasis Castration Resistant Prostate Cancer and Advanced Solid Tumors Who Have Progressed Following at Least One Prior Therapy
Lead sponsor
Hansoh BioMedical R&D Company
Phase
Phase 2
Overall status
Unknown status
Start date
January 18, 2024
Completion date
December 31, 2025
Enrollment
120 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

metastasis castration resistant prostate cancer(mcrpc)